Trustlife Ventures, Turkey's first company in the field of innovative drug development based on artificial intelligence and big data, continues to grow stronger with the investment of Alkima Partners (‘Alkima’).
Alkima is the second venture capital investment fund established in 2023 by the founding partners of Taxim Capital in order to establish partnerships in various proportions in medium-sized companies with high growth potential in Turkey. The total value of assets under management exceeds EUR 600 million at current values.
With the agreement finalised last week; Alkima invested USD 3 million in Trustlife. With this investment, the total amount of investment received by Trustlife since our establishment in 2021, including the investments of our founding team, has reached USD 16 million, taking into account the exchange rates on the relevant dates.
Trustlife currently carries out drug development activities for a total of 10 different cancers and rare diseases with a human resource of 71 people, 53 of whom are scientific researchers, in its own R&D facility based in Istanbul.
In 2025, we are working with all our strength to give good news to our country in this field.
